Department of Psychiatry, Mount Sinai School of Medicine, New York, New York 10029-6574, USA.
J Neurosci. 2009 Nov 25;29(47):14764-9. doi: 10.1523/JNEUROSCI.4291-09.2009.
There remains debate regarding the impact of cannabis on neuropsychiatric disorders. Here, we examined the effects of cannabidiol (CBD), a nonpsychoactive constituent of cannabis, on heroin self-administration and drug-seeking behavior using an experimental rat model. CBD (5-20 mg/kg) did not alter stable intake of heroin self-administration, extinction behavior, or drug seeking induced by a heroin prime injection. Instead, it specifically attenuated heroin-seeking behavior reinstated by exposure to a conditioned stimulus cue. CBD had a protracted effect with significance evident after 24 h and even 2 weeks after administration. The behavioral effects were paralleled by neurobiological alterations in the glutamatergic and endocannabinoid systems. Discrete disturbances of AMPA GluR1 and cannabinoid type-1 receptor expression observed in the nucleus accumbens associated with stimulus cue-induced heroin seeking were normalized by CBD treatment. The findings highlight the unique contributions of distinct cannabis constituents to addiction vulnerability and suggest that CBD may be a potential treatment for heroin craving and relapse.
关于大麻对神经精神疾病的影响仍存在争议。在这里,我们使用实验大鼠模型研究了大麻的非精神活性成分大麻二酚(CBD)对海洛因自我给药和觅药行为的影响。CBD(5-20mg/kg)并未改变海洛因自我给药的稳定摄入量、消退行为或海洛因引发的药物寻求。相反,它特别减弱了由条件刺激线索引发的海洛因寻求行为的恢复。CBD 具有持久的效果,在给药后 24 小时甚至 2 周后就有明显的效果。神经生物学研究发现,谷氨酸能和内源性大麻素系统发生变化,与线索诱导的海洛因寻求相关的伏隔核中 AMPA GluR1 和大麻素 1 型受体表达的离散干扰被 CBD 治疗所纠正。这些发现强调了不同大麻成分对成瘾易感性的独特贡献,并表明 CBD 可能是治疗海洛因渴望和复发的潜在药物。